• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Fitbit, FibriCheck Expand Partnership to Deliver CE-Marked Heart Health Detection App in Europe

Share:

March 9, 2020

Wearable leader Fitbit and FibriCheck, an innovative health screening and monitoring app, today announced they are expanding their partnership to enable users in France, Germany, Italy, and Spain to monitor their heart rhythm for irregularities, such as Atrial Fibrillation (AFib) directly from their Fitbit smartwatch. The FibriCheck software, which is CE marked, meets the performance standards for medical devices in the European Union (EU).

Impact of AFib in Europe

AFib, an irregular heart rhythm that is often difficult to detect or diagnose because of irregular occurrences, is a leading cause of stroke, the occurrence of which in Europe is predicted to increase to more than 800,000 by 2035[1]. The FibriCheck app for Fitbit smartwatches became available in September 2019 to Fitbit users in Belgium, Ireland, the Netherlands, and the UK. Since it launched on Fitbit OS, more than 150,000 heart rhythm measurements have been taken by users on their Fitbit smartwatch.

Check Your Heart Rhythm with Your Smartphone

The FibriCheck app runs on the Fitbit OS and uses Fitbit’s commercial-grade PPG (photoplethysmography) sensors – light-based technology that measures the rate of blood flow – to capture heart rhythm measurements from a user’s wrist. The measurement assessment can be viewed directly on the smartwatch screen and easily shared with medical professionals via a FibriCheck web interface to help diagnose conditions such as AFib.

The FibriCheck smartphone app has been available for users to measure their heart rhythm via the camera on their smartphones since 2016. A clinical trial was conducted to validate and support CE Marking of the FibriCheck application on Fitbit smartwatches. The trial compared FibriCheck on Fitbit smartwatches to gold-standard 12-lead ECG and state-of-the-art wearable single lead ECG technologies. The results indicated that the FibriCheck algorithm on Fitbit smartwatches was highly accurate in correctly detecting the presence of AFib when compared to ECG. As a result, this partnership between Fitbit and FibriCheck is expected to make trusted heart health monitoring accessible to more consumers in Europe.

Availability

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

FibriCheck will be available on Fitbit Versa™, Fitbit Versa Lite Edition™, Fitbit Versa 2™ and Fitbit Ionic™ devices and can be accessed through the Fitbit app gallery on smartphones. FibriCheck has a subscription model starting at €3.99 per month and a one-day free trial is available. A FibriCheck reading can be completed in 60 seconds. Instant, color-coded feedback is sent directly to the smartwatch screen; from green indicating that no irregularities have been detected, to red, which advises users to seek medical advice. A detailed report is also available via the FibriCheck smartphone app, which can be shared with medical professionals.

“For more than a decade, Fitbit has helped millions of people around the world take control of their health by providing them with a holistic picture of their health and wellness. Our partnership with FibriCheck expands on this vision by offering an accessible way for people to detect irregular heart rhythms using their Fitbit smartwatch, helping them to potentially identify and monitor heart conditions like Atrial Fibrillation,” said Nicola Maxwell, Director of Health Solutions & Services, EMEA for Fitbit.

Source: HIT Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Ashley Addiction Treatment acquires Washington, DC area outpatient provider, Aquila RecoveryAshley Addiction Treatment acquires Washington, DC area outpatient provider, Aquila Recovery
  • Eyevance Pharmaceuticals Acquires TOBRADEX® ST and NATACYN®Eyevance Pharmaceuticals Acquires TOBRADEX® ST and NATACYN®
  • Experian Health Launches AI-Driven Predictive Denials ManagementExperian Health Launches AI-Driven Predictive Denials Management
  • Life Launches AI Clinical Trial Matching Assistant for CancerLife Launches AI Clinical Trial Matching Assistant for Cancer
  • Blockchain 3.0 and COTI – Next Generation Technology Without Mining?Blockchain 3.0 and COTI – Next Generation Technology Without Mining?
  • BioAgilytix Closes Acquisition of Australia-Based 360Biolabs®BioAgilytix Closes Acquisition of Australia-Based 360Biolabs®
  • The Rise Of Use Of Medical Devices Force FDA To Change The RulesThe Rise Of Use Of Medical Devices Force FDA To Change The Rules
  • Empyrean Grabs $22M to Target CNS Disorders with Plant-Based PlatformEmpyrean Grabs $22M to Target CNS Disorders with Plant-Based Platform

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications